

Anita Mangia

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9445413/anita-mangia-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

1,822
citations

24
h-index

39
g-index

81
ext. papers

2,010
ext. citations

5.7
avg, IF

4.21
L-index

#	Paper	IF	Citations
76	Prognostic Value of NLRP3 Inflammasome and TLR4 Expression in Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021 , 11, 705331	5.3	6
75	The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a analysis of the IBIS 3 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835919888999	5.4	3
74	Tumor Infiltrating Lymphocytes and NHERF1 Impact on Prognosis of Breast Cancer Patients. <i>Translational Oncology</i> , 2020 , 13, 186-192	4.9	6
73	NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 1587	5.3	9
72	Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?. <i>Cancers</i> , 2019 , 11,	6.6	7
71	Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients. <i>Translational Oncology</i> , 2019 , 12, 585-595	4.9	19
70	Independent Negative Prognostic Role of TCF1 Expression within the Wnt/ β Catenin Signaling Pathway in Primary Breast Cancer Patients. <i>Cancers</i> , 2019 , 11,	6.6	6
69	NHERF1 Between Promises and Hopes: Overview on Cancer and Prospective Openings. <i>Translational Oncology</i> , 2018 , 11, 374-390	4.9	14
68	NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 96	12.8	13
67	Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers. <i>Translational Oncology</i> , 2018 , 11, 825-835	4.9	32
66	Frizzled-10 and cancer progression: Is it a new prognostic marker?. <i>Oncotarget</i> , 2018 , 9, 824-830	3.3	11
65	Bcl6/p53 expression, macrophages/mast cells infiltration and microvascular density in invasive breast carcinoma. <i>Oncotarget</i> , 2018 , 9, 22727-22740	3.3	8
64	VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients. <i>International Journal of Cancer</i> , 2017 , 141, 1901-1911	7.5	7
63	NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients. <i>Oncotarget</i> , 2017 , 8, 65730-65742	3.3	11
62	Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype. <i>Oncotarget</i> , 2017 , 8, 87782-87794	3.3	2
61	Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer. <i>Translational Oncology</i> , 2016 , 9, 453-457	4.9	73
60	Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?. <i>BMC Cancer</i> , 2016 , 16, 905	4.8	19

59	Nuclear PARP1 expression and its prognostic significance in breast cancer patients. <i>Tumor Biology</i> , 2016 , 37, 6143-53	2.9	22
58	Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. <i>Cancer Biology and Therapy</i> , 2016 , 17, 400-6	4.6	57
57	Ecatenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2016 , 7, 67841-67850	3.3	11
56	FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics. <i>Oncology Letters</i> , 2016 , 12, 3115-3122	2.6	8
55	Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients. <i>International Journal of Cancer</i> , 2016 , 138, 110-20	7.5	9
54	Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 79-86	4.4	15
53	Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. <i>European Journal of Cancer</i> , 2015 , 51, 1874-81	7.5	13
52	The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. <i>Cancer Biology and Therapy</i> , 2015 , 16, 1140-7	4.6	11
51	Fine Needle Aspiration Cytology: A Tool to Study NHERF1 Expression as a Potential Marker of Aggressiveness in Lung Cancer. <i>Molecular Biotechnology</i> , 2015 , 57, 549-57	3	15
50	Sister chromatid exchange: A possible approach to characterize familial breast cancer patients. <i>Oncology Reports</i> , 2015 , 33, 930-4	3.5	4
49	Immunoprofile from tissue microarrays to stratify familial breast cancer patients. <i>Oncotarget</i> , 2015 , 6, 27865-79	3.3	5
48	Benefit from anthracyclines in relation to biological profiles in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 307-18	4.4	18
47	CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 15767-77	6.3	18
46	The prognostic value of the Na ⁺ /H ⁺ exchanger regulatory factor 1 (NHERF1) protein in cancer. <i>Cancer Biomarkers</i> , 2014 , 14, 177-84	3.8	15
45	Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt376	9.7	62
44	Irradiation-induced angiosarcoma and anti-angiogenic therapy: a therapeutic hope?. <i>Experimental Cell Research</i> , 2014 , 321, 240-7	4.2	18
43	Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. <i>Gastroenterology</i> , 2013 , 144, 1497-507, 1507.e1-13	13.3	68
42	High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. <i>Journal of Cellular and Molecular Medicine</i> , 2013 , 17, 1025-37	5.6	62

41	Nuclear NHERF1 expression as a prognostic marker in breast cancer. <i>Cell Death and Disease</i> , 2013 , 4, e904	9.8	26
40	VEGF, HIF-1 α expression and MVD as an angiogenic network in familial breast cancer. <i>PLoS ONE</i> , 2013 , 8, e53070	3.7	51
39	Overexpression of nuclear NHERF1 in advanced colorectal cancer: association with hypoxic microenvironment and tumor invasive phenotype. <i>Experimental and Molecular Pathology</i> , 2012 , 92, 296-303	4.4	37
38	Involvement of nuclear NHERF1 in colorectal cancer progression. <i>Oncology Reports</i> , 2012 , 28, 889-94	3.5	22
37	Human epidermal growth factor receptor 2, Na ⁺ /H ⁺ exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers. <i>Human Pathology</i> , 2011 , 42, 1589-95	3.7	14
36	Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. <i>British Journal of Cancer</i> , 2011 , 104, 769-80	8.7	44
35	Tissue remodelling in breast cancer: human mast cell tryptase as an initiator of myofibroblast differentiation. <i>Histopathology</i> , 2011 , 58, 1096-106	7.3	61
34	Na ⁺ /H ⁺ exchanger regulatory factor 1 expression levels in blood and tissue predict breast tumour clinical behaviour. <i>Histopathology</i> , 2011 , 58, 1086-95	7.3	18
33	Gene copy number variation in male breast cancer by aCGH. <i>Cellular Oncology (Dordrecht)</i> , 2011 , 34, 467-73	7.3	7
32	Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib. <i>Clinical Biochemistry</i> , 2011 , 44, 936-40	3.5	9
31	Old and new concepts in histopathological characterization of familial breast cancer. <i>Annals of Oncology</i> , 2011 , 22 Suppl 1, i24-30	10.3	11
30	Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer. <i>Oncology Reports</i> , 2010 , 23, 1641-5	3.5	5
29	Gene Copy Number Variation in Male Breast Cancer by aCGH. <i>Analytical Cellular Pathology</i> , 2010 , 33, 113-119	3.4	15
28	Research Trends for Early Cancer Biomarker Detection in Italy: An Integrated Program in Oncology (PIO) Survey. <i>Tumori</i> , 2010 , 96, 721-725	1.7	
27	Biomarkers for Early Cancer Detection - Methodological Aspects. <i>Breast Care</i> , 2010 , 5, 62-65	2.4	8
26	Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010 , 29, 125	12.8	12
25	NHERF1/EBP50 in Breast Cancer: Clinical Perspectives. <i>Breast Care</i> , 2010 , 5, 86-90	2.4	29
24	Biological role of NHERF1 protein expression in breast cancer. <i>Histopathology</i> , 2009 , 55, 600-8	7.3	50

23	Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. <i>Molecular Cancer</i> , 2009 , 8, 29	42.1	27
22	The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. <i>International Journal of Biological Markers</i> , 2009 , 24, 119-29	2.8	5
21	Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers. <i>Cancer Genetics and Cytogenetics</i> , 2008 , 182, 75-83		12
20	Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. <i>Journal of Molecular Diagnostics</i> , 2008 , 10, 527-36	5.1	34
19	SELDI-TOF serum proteomics and breast cancer: which perspective?. <i>Expert Review of Proteomics</i> , 2008 , 5, 779-85	4.2	18
18	Touch imprint cytology in tumor tissue banks for the confirmation of neoplastic cellularity and for DNA extraction. <i>Archives of Pathology and Laboratory Medicine</i> , 2008 , 132, 974-8	5	9
17	Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. <i>International Journal of Cancer</i> , 2007 , 120, 2078-85	7.5	119
16	Phosphatidylinositol 3-kinase in breast cancer: where from here?. <i>Clinical Cancer Research</i> , 2007 , 13, 5988-90	2.9	12
15	The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. <i>Molecular Biology of the Cell</i> , 2007 , 18, 1768-80	3.5	114
14	H pylori status and angiogenesis factors in human gastric carcinoma. <i>World Journal of Gastroenterology</i> , 2006 , 12, 5465-72	5.6	8
13	3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 172, 738-44	10.2	70
12	Prognostic relevance of histological grade and its components in node-negative breast cancer patients. <i>Modern Pathology</i> , 2004 , 17, 1038-44	9.8	31
11	Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. <i>International Journal of Cancer</i> , 2004 , 111, 252-8	7.5	41
10	Prognostic relevance of mitotic activity in patients with node-negative breast cancer. <i>Modern Pathology</i> , 2003 , 16, 1067-75	9.8	36
9	HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2708-12	2.2	41
8	Gonadotropin releasing hormone receptor expression in primary breast cancer: comparison of immunohistochemical, radioligand and Western blot analyses. <i>Oncology Reports</i> , 2002 , 9, 1127-32	3.5	18
7	Failure of primary breast cancer neoangiogenesis to predict pattern of distant metastasis. <i>Clinical and Experimental Medicine</i> , 2001 , 1, 127-32	4.9	5
6	Predictability of monthly and yearly rhythms of breast cancer features. <i>Breast Cancer Research and Treatment</i> , 2001 , 67, 41-9	4.4	8

5	Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3929-37	2.2	35
4	Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity. <i>Tumor Biology</i> , 1993 , 14, 30-7	2.9	8
3	Mammographic aspect, cell kinetics and hormone receptor status of operable breast cancer. <i>Oncology</i> , 1993 , 50, 104-9	3.6	5
2	Cytosol cathepsin-D content and proliferative activity of human breast cancer. The Comitato Italiano per il Controllo di Qualita del Laboratorio in Oncologia. <i>Breast Cancer Research and Treatment</i> , 1992 , 23, 63-70	4.4	7
1	Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. <i>Cancer</i> , 1989 , 64, 1922-7	6.4	62